Janssen to Present Data from its Robust Oncology Portfolio and Pipeline at the 24th EHA Annual Congress


BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson have announced the latest research to be presented at the 24th European Hematology Association (EHA) Annual Congress taking place in Amsterdam, The Netherlands, from 13–16 June 2019. Janssen will present 28 company-sponsored abstracts from its leading haematological malignancy portfolio at the congress, including the latest results for DARZALEX® (daratumumab) and IMBRUVICA® (ibrutinib). “With more th…